This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Plunkett's Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies

7) Gene Therapies and Patients' Genetic Profiles Promise a Personalized Approach to Medicine

8) Breakthrough Drugs for Cancer Treatment—Many More Will Follow

9) Few New Blockbusters: Major Drug Patents Expire While Generic Sales Growth Continues

10) Biotech and Orphan Drugs Pick Up the Slack as Blockbuster Mainstream Drugs Age

11) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce

12) Breakthrough New Drug Delivery Systems Evolve

13) Stem Cells—Multiple Sources Stem from New Technologies

14) Government Support for Stem Cell Research Evolves

15) Stem Cells—Therapeutic Cloning Techniques Advance

16) Stem Cells—A New Era of Regenerative Medicine Takes Shape

17) Nanotechnology Converges with Biotech

18) Agricultural Biotechnology Scores Breakthroughs but Causes Controversy/Selective Breeding Offers a Compromise

19) Focus on Vaccines

20) Technology Discussion—Genomics

21) Technology Discussion—Proteomics

22) Technology Discussion—Microarrays

23) Technology Discussion—DNA Chips

24) Technology Discussion—SNPs ("Snips")

25) Technology Discussion—Combinatorial Chemistry

26) Technology Discussion—Synthetic Biology

27) Technology Discussion—Recombinant DNA

28) Technology Discussion—Polymerase Chain Reaction (PCR)

Biotech & Genetics Industry Statistics

1) Biotech Industry Overview

2) The U.S. Drug Discovery & Approval Process

3) U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2011

4) U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals:1993-2011

5) Employment in Life & Physical Science Occupations, U.S.: May 2011

6) Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2011-2013

7) U.S. Exports & Imports of Pharmaceutical Products: 2007-1st Quarter 2012

8) U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2006-2021

9) U.S. Prescription Drug Expenditures: 1970-2021

10) Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2011

11) Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2011-2013

12) Global Area of Biotech Crops by Country: 2011

13) Biologics & Biotechnology R&D, PhRMA Member Companies: 2010

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs